Where does Oruka Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$116.25M+25.3%	-$105.43M+25.6%	-$159.57M-170%	-$157.92M-396%	-$155.59M-1,306%
Depreciation and amortization	$110K+93.0%	$83K+88.6%	$82K+310%	$73K+462%	$57K+307%
Stock-based compensation	$26.33M-13.2%	$24.24M-5.1%	$35.04M+226%	$34.65M+2,918%	$30.34M+5,251%
Change in accrued liabilities	——	——	——	——	$7.94M—
Change in other assets	——	——	——	——	$189K—
Change in other liabilities	$117K-98.4%	$693K-90.3%	$2.21M—	$6.29M—	$7.19M—
Change in operating lease liabilities	-$572K-2,188%	-$468K—	-$482K—	-$37K—	-$25K—
Net cash from operating activities	-$90.92M+29.5%	-$88.21M+18.5%	-$123.45M-140%	-$140.87M-900%	-$128.93M-3,494%
Capital expenditures	$269K—	$209K—	$335K—	$407K—	——
Purchases of investments	$567.5M—	$520.96M—	$749.91M—	——	——
Proceeds from maturities/sales of investments	$413.72M—	$424.42M—	——	——	——
Acquired in-process research and development	$109.86M-21.2%	$100.64M-19.2%	$148.06M—	$144.76M—	$139.35M—
Net cash from investing activities	-$154.05M+46.4%	-$96.75M+70.7%	-$404.85M—	-$282.57M—	-$287.43M—
Proceeds from issuance of common stock	——	——	——	——	——
Net cash from financing activities	——	——	——	——	——
Net increase (decrease) in cash	-$34.05M-107%	-$14.64M-103%	$91.25M-78.4%	$476.27M+4,282%	$509.57M+10,401%
Accretion (Amortization) of Discounts and Premiums, Investments	$3.65M—	$5M—	$6.59M—	——	——
Stock-based compensation	$26.33M-10.7%	$24.24M-1.8%	$35.04M—	$33.88M—	$29.49M—
Depreciation	$110K—	$83K—	$82K—	$73K—	——
Increase Decrease In Accounts Payable Related Parties	$2.19M-90.3%	-$6.01M-118%	$8K—	$6.48M—	$22.61M—
Accrued expenses and other liabilities	——	——	——	——	$7.94M+3,430%
Operating lease liabilities	-$572K-2,188%	-$468K—	-$482K—	-$37K—	-$25K—
Increase Decrease In Other Accounts Payable	$117K-98.4%	$693K-90.3%	$2.21M—	$6.29M—	$7.19M—
Increase (Decrease) in Prepaid Expense and Other Assets	$3.36M-32.4%	$3.97M—	$4.3M—	$3.87M—	$4.98M—
Payment-in-kind interest	——	——	——	——	——
Proceeds From Atthemarket Offering Net Of Commissions	——	——	——	——	——
Exchange Offer (Note 12)	——	——	——	——	——
Costs And Expenses Related Party	——	——	——	——	——
General and administrative costs	$23.54M-5.1%	$21.41M+0.5%	$27.68M—	$26.32M—	$24.8M—
Income/(loss) from affiliates	——	$54K—	$116.5K—	——	——
Other	——	$949K—	-$19.25K—	——	——
Investment Income Interest	$17.14M—	$16.63M—	$17.64M—	$15.14M—	——
Non Cash Lease Expense	——	——	——	——	——
Other Income - Net	$17.15M+100%	$16.62M+290%	$16.17M—	$13.17M—	$8.56M—
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax	-$474K—	$587K—	$185K—	——	——
Issuance of warrants	——	$10.07M—	$17.91M—	——	——
Free cash flow	-$91.19M—	-$88.42M—	-$123.79M—	-$141.28M—	——
Free cash flow	-$91.19M—	-$88.42M—	-$123.79M—	-$141.28M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Oruka Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.